Ipilimumab at a dose of 3 mg/kg can be infused safely over 30 minutes, rather than 90 minutes, with an acceptably low incidence of infusion-related reactions, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
Because ipilimumab at a dose of 10 mg/kg has been infused over 90 minutes in clinical trials, researchers sought to investigate the safety of infusing ipilimumab at a dose of 3 mg/kg over 30 minutes.
For the study, researchers at Memorial Sloan-Kettering Cancer Center in New York, NY, retrospectively evaluated the incidence of infusion-related reactions at Memorial Sloan-Kettering in 595 patients who received ipilimumab at a dose of 3 or 10 mg/kg infused over 90 minutes.
Results showed that 595 patients received 2,507 3 mg/kg or 10 mg/kg doses of ipilimumab infused over 90 minutes.
Researchers found that 4.3% of patients who received 10 mg/kg experienced infusion-related reactions compared with 2.2% of those who received 3 mg/kg (P=0.22).
RELATED: Increased Risk of Infusion Site Reactions with Fosaprepitant in Patients Receiving Anthracyclines
Researchers then prospectively evaluated 120 patients treated with ipilimumab 3 mg/kg infused over 30 minutes. Of those, seven (5.8%) patients experienced an infusion-related reaction (P=0.06 versus 90-minute infusion).
The study also demonstrated that after an infusion-related reaction, patients can safely receive subsequent doses of ipilimumab with premedication.